Cross-sectional and longitudinal analyses of urinary extracellular vesicle mRNA markers in urothelial bladder cancer patients.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Non-Muscle Invasive Bladder Neoplasms* ; Urinary Bladder Neoplasms*/pathology ; Carcinoma, Transitional Cell*; Humans ; Prospective Studies ; Cross-Sectional Studies ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/pathology ; Biomarkers ; Neoplasm Invasiveness ; Receptors, G-Protein-Coupled

We designed this multi-center prospective study with the following objectives: (1) the cross-sectional validation of extracellular vesicles (EV) mRNA markers to detect urothelial bladder cancer (UBC) before transurethral resection of bladder cancer (TURBT), and (2) the longitudinal validation of EV mRNA markers to monitor non-muscle invasive bladder cancer (NMIBC) recurrence after TURBT. EV mRNA markers evaluated in this study were KRT17, GPRC5A, and SLC2A1 in addition to two additional markers from literatures, MDK and CXCR2, and measured by quantitative RT-PCR with normalization by a reference gene (ALDOB). Diagnostic performances of EV mRNA markers were compared to conventional markers. Regarding the first objective, we confirmed that EV mRNA biomarkers in urine were higher in UBC patients, particularly those with higher stage/grade tumors, than in those without UBC (n = 278 in total) and the diagnostic performance of EV mRNA MDK and KRT17 outperformed conventional biomarkers with AUC 0.760 and 0.730, respectively. Concerning the second objective, we prospectively analyzed the time courses of EV mRNA markers while NMIBC patients (n = 189) (median follow-up 19 months). The expression of EV mRNA KRT17 was significantly high in patients with recurrence, while it gradually decreased over time in those without recurrence (p < 0.01).
(© 2024. The Author(s).)

BMC Med Res Methodol. 2015 May 12;15:45. (PMID: 25962444)
Pharmacoeconomics. 2003;21(18):1315-30. (PMID: 14750899)
PLoS One. 2014 Nov 14;9(11):e110641. (PMID: 25397880)
Oncotarget. 2015 Nov 10;6(35):37151-68. (PMID: 26452221)
Acta Cytol. 2016;60(3):185-97. (PMID: 27318895)
Ann Surg Oncol. 2010 Jun;17(6):1471-4. (PMID: 20180029)
Transl Androl Urol. 2021 Apr;10(4):1878-1889. (PMID: 33968676)
JAMA. 2020 Nov 17;324(19):1980-1991. (PMID: 33201207)
J Natl Compr Canc Netw. 2022 Aug;20(8):866-878. (PMID: 35948037)
Urol Oncol. 2021 Jan;39(1):41-51. (PMID: 32919875)
Science. 1945 May 18;101(2629):519-20. (PMID: 17775845)
Cancer Manag Res. 2019 Aug 07;11:7485-7497. (PMID: 31496806)
Transl Cancer Res. 2021 Oct;10(10):4489-4501. (PMID: 35116305)
Urol Oncol. 2008 Nov-Dec;26(6):646-51. (PMID: 18367109)
Int J Urol. 2020 Sep;27(9):702-709. (PMID: 32564429)
Mod Pathol. 2019 May;32(5):717-724. (PMID: 30443013)
Onco Targets Ther. 2021 Jan 19;14:577-587. (PMID: 33500631)
Oncotarget. 2018 Aug 28;9(67):32810-32821. (PMID: 30214686)
Carcinogenesis. 2020 Jul 10;41(5):591-599. (PMID: 31754689)
PLoS One. 2014 Oct 02;9(9):e109074. (PMID: 25275511)

22K09439 Japan Society for the Promotion of Science

Keywords: Biomarker; Cancer recurrence; Exosome; Extracellular vesicles; Non-muscle invasive bladder cancer; mRNA

0 (Biomarkers)
0 (GPRC5A protein, human)
0 (Receptors, G-Protein-Coupled)

Date Created: 20240322 Date Completed: 20240325 Latest Revision: 20240325

20240325

PMC10957914

10.1038/s41598-024-55251-x

38514751